Biotech Values

[DewDiligence]

GSK’s 1Q14 Advair sales decreased 15% YoY due, in part, to ESRX’s machinations:

http://online.wsj.com/news/articles/SB10001424052702303678404579533351680164572

In the U.S, pharmacy-benefit manager Express Scripts Holding Co —which negotiates drug prices on behalf of employers and health insurers—took the Glaxo inhalers Advair Diskus, Flovent Diskus and Breo Ellipta off its "preferred drug" list as of Jan. 1, meaning patients prescribed them must pay full retail prices for the drugs. Express Scripts recommends rival treatments instead, including Symbicort from AstraZeneca and Dulera from Merck.